Page 2 - Torrent Pharma

Torrent Pharma expected to enter diagnostics space in next 2-3 months

A company called Torrent Diagnostics Private Ltd was incorporated in February this year and has a Torrent Pharmaceuticals executive director as one of its directors

Nifty can target 16,650 in the short-term, says Vinay Rajani

The technical analyst from HDFC Securities also recommends buying CCL Products and Torrent Pharma.

Strong domestic outlook remains key growth driver for Torrent Pharma

Cost savings could drive Torrent Pharma's margins higher in the near term

Torrent Pharma's domestic show remains strong, brokerages turn positive

Progress on US sales will be key for further Torrent Pharma's stock gains

Stocks to Watch: RIL, HUL, Dr.Reddy's, PNB Housing, Future Retail, Banks

Reliance Industries is likely to be in limelight as the company is looking to take advantage of the surging diesel demand in Europe in the backdrop of Russia-Ukraine conflict.

Sensex slips 581 pts amid hawkish US Fed, F&O expiry; Nifty holds 17,100

Sectorally, the Nifty PSU Bank index jumped a massive 5 per cent on the NSE, while the Nifty Bank and Private Bank indices added about a per cent each

Torrent Pharma tumbles 14% on disappointing Q3 results

In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in the US.

Torrent Pharma net profit drops 16% to Rs 249 crore in third quarter

The company's revenue from operations in the third quarter stood at Rs 2,108 crore as compared to Rs 1,995 crore in the same period of previous fiscal

Sensex snaps 5-day losing run, ends 367 pts up; Nifty holds 17,250

Bargain buying in banking and auto counters amid better-than-expected Q3 results by Axis Bank and Maruti Suzuki pushed the index 367 points higher at 57,858 level at close

Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high

Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI

Torrent Pharma Q2 PAT up just 2% to Rs 316 cr on drop in US sales

Overall revenues up 6% YoY, while those in US dropped by as much as 13%

Torrent Pharma gains 3% in a weak market on healthy margins in June quarter

The company has launched baricitinib during the quarter and is currently conducting clinical trials for molnupiravir; more partnerships under evaluation to widen Covid portfolio

Torrent Pharma Q1 net grows marginally by 3% as price erosion in US weighs

The company's revenues also grew in single digits at four per cent, from Rs 2,056 crore in Q1 of FY21 to Rs 2,134 crore in Q1 of FY22

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

These are scheduled drugs (or ones that are under price control) and low priced

Cipla, Dr Reddy's Labs: Tech charts show up to 11% upside in pharma stocks

After hitting a new all-time high of Rs 997 earlier today, the stock of Cipla is all set to rally towards Rs 1,100

Hope to launch diabetic NCE by next financial year: Torrent Pharma's Mehta

We would also look into distribution opportunities to bring some of these products into the market, said Mehta

Torrent Pharma shares rise 6% post March quarter results

HDFC Securities said that Torrent's Q4 results were largely in line with their estimates as strong trends in India and Germany offset weak US

Torrent Pharma's Q4 consolidated net profit up 3 pc at Rs 324 crore

Drug firm Torrent Pharma reported a 3.18 per cent rise in its consolidated net profit to Rs 324 crore for the quarter ended March 31, 2021

Torrent Pharma inks pact with Eli Lilly for Covid drug Baricitinib in India

Under royalty-free, non-exclusive deal, Torrent can make and sell baricitinib in India along with the US firm's other license partners

Nifty outlook & trading ideas by Gaurav Garg of CapitalVia Global Research

Nifty index can witness profit booking only if it breaks level of 14,800